GlassScriptPhysician profile
David M Scheidler
NPI 1750395299
$4,336.07
in general payments reported to CMS, 2019-2025
41 companies · $16.23 in 2025
The $16.23 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,351 · 2020: $510 · 2021: $361 · 2022: $598 · 2023: $1,402 · 2024: $97.90 · 2025: $16.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,516.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $738.97 | 2019-2023 | Xtandi |
| Janssen Biotech, INC. | $617.77 | 2019-2023 | Erleada, Akeega |
| Bayer Healthcare Pharmaceuticals INC. | $418.19 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $281.57 | 2023-2024 | Orgovyx, Gemtesa |
| Merck Sharp & Dohme LLC | $242.76 | 2019-2023 | Lynparza, Keytruda, Welireg |
| Pfizer INC. | $208.42 | 2019-2023 | |
| Tolmar Pharmaceuticals, INC. | $205.12 | 2019-2022 | |
| Myriad Genetic Laboratories, INC. | $158.11 | 2021-2023 | Prolaris |
| Abbvie INC. | $134.32 | 2019-2023 | Botox |
| Urogen Pharma, INC. | $101.93 | 2021-2024 | Jelmyto |
| Photocure INC | $98.17 | 2019 | |
| Genzyme Corporation | $88.33 | 2019-2023 | |
| Coloplast Corp | $75.62 | 2023-2025 | Speedicath |
| Zyla Life Sciences, INC. | $73.03 | 2019 | |
| Amgen INC. | $65.27 | 2019 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Scheidler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.